SBIR-STTR Award

LFMA: Microfluidics-Enabled Microarrays
Award last edited on: 10/29/09

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$292,450
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Rajan Kumar

Company Information

Genome Data Systems Inc (AKA: GDS)

127 US Highway 206 Suite 29
Hamilton, NJ 08610
   (609) 581-6861
   rkumar@genomedatasystems.com
   www.genomedatasystems.com
Location: Single
Congr. District: 04
County: Mercer

Phase I

Contract Number: 1R43GM078945-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2007
Phase I Amount
$205,908
This application proposes a novel approach to address the highly significant problem of microarray signal variation. Future advances in human health will that use knowledge gained from whole genome molecular analysis. Whole genome expression analysis using DNA microarrays has enabled rapid functional genomic studies and will provide the following significant

Benefits:
discovery of new drugs to combat complex diseases such as cancer, diabetes and cardiovascular disorders, identification of new biomarkers leading to rapid molecular diagnostics and personalized medicine, and development of new strategies to identify and ameliorate effect of environmental toxins. However, current microarray technology has significant problems that limit their applicators. We propose to investigate improvements in microarray sensitivity and specificity using a method called Laminar flow Microarray Analysis (LFMA). This application has these specific aims 1) fabricate devices and systems that allow laminar flow studies of microarrays, 2) investigate effects of LFMA on microarray hybridization performance, and; 3) compare the performance of laminar flow hybridization with conventional static hybridization methods. We believe that successful development of LFMA will open the following commercial avenues for us: sale of disposable LFMA devices, automated instrument, and reagent kits, and provide laminar flow microarray analyses as a service. DNA microarray technology is a powerful method for whole genome expression analysis. After the completion of human genome sequencing, advances in human health will depend upon technologies that use knowledge gained from whole genome molecular analysis. Rapid functional genomic studies using microarrays will provide the following significant

Benefits:
Discovery of new drugs to combat complex diseases such as cancer, diabetes and cardiovascular disorders; Identification of new biomarkers leading to rapid molecular diagnostics and personalized medicine; Development of new strategies to identify and ameliorate effect of environmental toxins

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
$86,542